- Home
- PRTC vs EQV Comparison
PRTC vs EQV Comparison
Compare PRTC & EQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTC
- EQV
- Stock Information
- Founded
- PRTC 2015
- EQV 2024
- Country
- PRTC United States
- EQV United States
- Employees
- PRTC N/A
- EQV N/A
- Industry
- PRTC Biotechnology: Pharmaceutical Preparations
- EQV
- Sector
- PRTC Health Care
- EQV
- Exchange
- PRTC Nasdaq
- EQV Nasdaq
- Market Cap
- PRTC 439.8M
- EQV 472.5M
- IPO Year
- PRTC N/A
- EQV 2024
- Fundamental
- Price
- PRTC $17.90
- EQV $10.62
- Analyst Decision
- PRTC Buy
- EQV
- Analyst Count
- PRTC 1
- EQV 0
- Target Price
- PRTC $45.00
- EQV N/A
- AVG Volume (30 Days)
- PRTC 2.0K
- EQV 209.9K
- Earning Date
- PRTC 04-30-2025
- EQV 01-01-0001
- Dividend Yield
- PRTC N/A
- EQV N/A
- EPS Growth
- PRTC N/A
- EQV N/A
- EPS
- PRTC 0.21
- EQV N/A
- Revenue
- PRTC $4,828,000.00
- EQV N/A
- Revenue This Year
- PRTC $35.98
- EQV N/A
- Revenue Next Year
- PRTC $115.38
- EQV N/A
- P/E Ratio
- PRTC $7.81
- EQV $51.68
- Revenue Growth
- PRTC 44.98
- EQV N/A
- 52 Week Low
- PRTC $13.30
- EQV $9.88
- 52 Week High
- PRTC $28.39
- EQV $10.74
- Technical
- Relative Strength Index (RSI)
- PRTC 46.07
- EQV N/A
- Support Level
- PRTC $19.00
- EQV N/A
- Resistance Level
- PRTC $19.80
- EQV N/A
- Average True Range (ATR)
- PRTC 0.33
- EQV 0.00
- MACD
- PRTC -0.12
- EQV 0.00
- Stochastic Oscillator
- PRTC 16.30
- EQV 0.00
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
About EQV EQV Ventures Acquisition Corp.
EQV Ventures Acquisition Corp is a blank check company.